Central Nervous System Biomarkers Global Market Report 2025

Description

Central nervous system (CNS) biomarkers are specific substances or measurable indicators within the CNS that offer insights into normal functioning, disease processes, or responses to treatments. They play a crucial role in diagnosing or predicting neurological disorders, monitoring disease progression, and anticipating responses to drug therapy.

The primary categories of CNS biomarkers include safety biomarkers, efficacy biomarkers, validation biomarkers, and others. Safety biomarkers encompass measurable biological parameters or indicators employed to evaluate the safety of drugs, medical interventions, or environmental exposures. They find application in treating various diseases such as multiple sclerosis, Alzheimer's disease, traumatic brain injury, and more, contributing to drug discovery and development, personalized medicines, disease risk assessment, diagnostics, among other areas. Diverse end-users, such as diagnostic labs, clinics, hospitals, research centers, and others, utilize these biomarkers.

The central nervous system biomarkers market research report is one of a series of new reports from The Business Research Company that provides central nervous system biomarkers market statistics, including central nervous system biomarkers industry global market size, regional shares, competitors with a central nervous system biomarkers market share, detailed central nervous system biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the central nervous system biomarkers industry. This central nervous system biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The central nervous system biomarkers market size has grown rapidly in recent years. It will grow from $5.58 billion in 2024 to $6.15 billion in 2025 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to rise in concerns regarding neurological disorders, high prevalence of central nervous system illnesses, growth in demand for enhanced diagnosis and treatment, improved healthcare infrastructure, rise in aging population

The central nervous system biomarkers market size is expected to see strong growth in the next few years. It will grow to $9 billion in 2029 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to increasing prevalence of neurological disorders, growing demand for personalized medicine, rising geriatric population, increasing focus on early diagnosis, growing demand for non-invasive diagnostic tools. Major trends in the forecast period include new technological advancements, strategic collaborations between biotechnology companies, pharmaceutical companies, and other stakeholders, growth in research on cerebrospinal fluid (csf) and blood-based biomarkers, utilization of ai and machine learning algorithms.

The anticipated increase in neurological illnesses is expected to drive the expansion of the central nervous system biomarker market in the future. Neurological illnesses, also referred to as neurological disorders, encompass a broad spectrum of conditions affecting the brain, spinal cord, and nerves throughout the body. These disorders can result from various factors, including genetic influences, infections, autoimmune responses, degenerative processes, tumors, vascular issues, and traumatic injuries. In the realm of neurological disorders, central nervous system (CNS) biomarkers play a crucial role in clinical diagnosis, determining illness risk or prognosis, assessing disease stage, and monitoring treatment response. They contribute significantly to comprehending these diseases and their treatability. For instance, in April 2023, the Centers for Disease Control and Prevention, a US government agency, reported that Alzheimer's disease affected an estimated 6.7 million Americans aged 65 and older, with projections indicating a tripling of this number to 14 million by 2060. Furthermore, the incidence of the disease is observed to double every five years after the age of 65. Consequently, the surge in neurological illnesses is a key factor propelling the growth of the central nervous system biomarker market.

The growing prevalence of obesity is expected to fuel the expansion of the central nervous system biomarker market in the coming years. Obesity, a medical condition marked by an excess of body fat, can adversely affect an individual's health. Central nervous system biomarkers are employed to study obesity, aiding in the understanding of the neurological mechanisms that control body weight and eating behavior, as well as in the development of effective anti-obesity treatments. For example, in March 2023, the World Heart Foundation, a Switzerland-based global cardiovascular organization, reported that approximately 2.3 billion adults and children worldwide are either obese or overweight. With current obesity trends, it is projected that the number of people affected by obesity will rise to 2.7 billion by 2025. Thus, the increasing prevalence of obesity is driving the growth of the central nervous system biomarker market.

A prominent trend gaining traction in the central nervous system biomarker market is the approval of innovative drugs. Leading companies in the market are dedicated to developing groundbreaking drugs and obtaining approvals to enhance their market standing. For example, in January 2022, Denovo Biopharma LLC, a clinical-stage biopharmaceutical company based in the US, disclosed the approval and authorization of its investigational new drug (IND) application for DB104 (liafensine) by the US Food and Drug Administration (FDA) for treating treatment-resistant depression (TRD). This marks the initiation of the first biomarker-guided global CNS clinical trial for TRD. The drug has the potential to identify patients more likely to respond to liafensine, facilitating more personalized treatment decisions. Liafensine, a novel compound, functions by elevating levels of dopamine and norepinephrine in the brain.

Major players in the central nervous system biomarker market are strategically focused on introducing advanced solutions, such as assay kits. An assay kit is a pre-packaged set of reagents and materials utilized for a specific scientific analysis. For instance, in June 2023, Sysmex Corporation, a research and development company based in Japan, launched an Automated Immunoassay System. This assay kit is designed to detect amyloid beta (AB) accumulation in the brain, a contributor to Alzheimer's disease, using a small blood sample. The kit measures the ratio of AB peptides in the blood through an automated immunoassay system. This facilitates clinicians in identifying AB accumulation in the brain with a minimal blood sample, enabling earlier diagnosis and treatment for patients.

In June 2022, Fujirebio Holdings Inc., a biotechnology company based in Japan, acquired ADx NeuroSciences for approximately $43 million (40 million euros). This acquisition aims to broaden Fujirebio Holdings' portfolio of central nervous system biomarkers, leverage ADx NeuroSciences' expertise and technology, and enhance its global presence in the central nervous system biomarker market. ADx NeuroSciences, headquartered in Belgium, is a biomarker-assay company specializing in the development and production of biomarkers for central nervous system (CNS) disorders.

Major companies operating in the central nervous system biomarkers market include F. Hoffmann-La Roche AG, Novartis AG, Siemens Healthineers, Thermo Fisher Scientific Inc, Abbott Laboratories, Merck KGaA, Eurofins Scientific, Charles River Laboratories International Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Axon Neuroscience SE, Alector Inc., Oryzon Genomics S.A., Abastar Mdx Inc., Banyan Biomarkers Inc., Avacta Group PLC, Geno Technology Inc., Anavex Life Sciences Corp., Alseres Pharmaceuticals Inc., Aposense Ltd., Applied Neurosolutions Inc., C2N Diagnostics, Alzheon Inc., DiaGenic ASA, Abiant Inc., Avid Radiopharmaceuticals Inc., Acumen Pharmaceuticals Inc., Cassava Sciences Inc., Denali Therapeutics

North America was the largest region in the central nervous system biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the central nervous system biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the central nervous system biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The central nervous system biomarkers market consists of sales of diagnostic test kits, assay reagents, antibody drugs, and imaging agents. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Central Nervous System Biomarkers Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on central nervous system biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for central nervous system biomarkers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The central nervous system biomarkers market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Safety Biomarker; Efficacy Biomarker; Validation Biomarker; Other Types
2) By Disease: Multiple Sclerosis; Alzheimer's Disease; Parkinson's Disease; Traumatic Brain Injury; Other Diseases
3) By Application: Drug Discovery And Development; Personalized Medicines; Disease Risk Assessment; Diagnostics; Other Applications
4) By End-Users: Diagnostic Labs; Clinics; Hospitals; Research Centers; Other End-Users
Subsegments:
1) By Safety Biomarker: Toxicity Biomarkers; Adverse Event Biomarkers
2) By Efficacy Biomarker: Pharmacodynamic Biomarkers; Response Biomarkers
3) By Validation Biomarker: Predictive Biomarkers; Prognostic Biomarkers
4) By Other Types: Diagnostic Biomarkers; Biomarkers For Disease Progression
Companies Mentioned: F. Hoffmann-La Roche AG; Novartis AG; Siemens Healthineers; Thermo Fisher Scientific Inc; Abbott Laboratories
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r24784

1. Executive Summary

2. Central Nervous System Biomarkers Market Characteristics

3. Central Nervous System Biomarkers Market Trends And Strategies

4. Central Nervous System Biomarkers Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Central Nervous System Biomarkers Growth Analysis And Strategic Analysis Framework

5.1. Global Central Nervous System Biomarkers PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Central Nervous System Biomarkers Market Growth Rate Analysis
5.4. Global Central Nervous System Biomarkers Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Central Nervous System Biomarkers Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Central Nervous System Biomarkers Total Addressable Market (TAM)

6. Central Nervous System Biomarkers Market Segmentation

6.1. Global Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Safety Biomarker
Efficacy Biomarker
Validation Biomarker
Other Types
6.2. Global Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Multiple Sclerosis
Alzheimer's Disease
Parkinson's Disease
Traumatic Brain Injury
Other Diseases
6.3. Global Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Drug Discovery And Development
Personalized Medicines
Disease Risk Assessment
Diagnostics
Other Applications
6.4. Global Central Nervous System Biomarkers Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Diagnostic Labs
Clinics
Hospitals
Research Centers
Other End-Users
6.5. Global Central Nervous System Biomarkers Market, Sub-Segmentation Of Safety Biomarker, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Toxicity Biomarkers
Adverse Event Biomarkers
6.6. Global Central Nervous System Biomarkers Market, Sub-Segmentation Of Efficacy Biomarker, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pharmacodynamic Biomarkers
Response Biomarkers
6.7. Global Central Nervous System Biomarkers Market, Sub-Segmentation Of Validation Biomarker, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Predictive Biomarkers
Prognostic Biomarkers
6.8. Global Central Nervous System Biomarkers Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Diagnostic Biomarkers
Biomarkers For Disease Progression

7. Central Nervous System Biomarkers Market Regional And Country Analysis

7.1. Global Central Nervous System Biomarkers Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Central Nervous System Biomarkers Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Central Nervous System Biomarkers Market

8.1. Asia-Pacific Central Nervous System Biomarkers Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Central Nervous System Biomarkers Market

9.1. China Central Nervous System Biomarkers Market Overview
9.2. China Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Central Nervous System Biomarkers Market

10.1. India Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Central Nervous System Biomarkers Market

11.1. Japan Central Nervous System Biomarkers Market Overview
11.2. Japan Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Central Nervous System Biomarkers Market

12.1. Australia Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Central Nervous System Biomarkers Market

13.1. Indonesia Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Central Nervous System Biomarkers Market

14.1. South Korea Central Nervous System Biomarkers Market Overview
14.2. South Korea Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Central Nervous System Biomarkers Market

15.1. Western Europe Central Nervous System Biomarkers Market Overview
15.2. Western Europe Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Central Nervous System Biomarkers Market

16.1. UK Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Central Nervous System Biomarkers Market

17.1. Germany Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Central Nervous System Biomarkers Market

18.1. France Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Central Nervous System Biomarkers Market

19.1. Italy Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Central Nervous System Biomarkers Market

20.1. Spain Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Central Nervous System Biomarkers Market

21.1. Eastern Europe Central Nervous System Biomarkers Market Overview
21.2. Eastern Europe Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Central Nervous System Biomarkers Market

22.1. Russia Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Central Nervous System Biomarkers Market

23.1. North America Central Nervous System Biomarkers Market Overview
23.2. North America Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Central Nervous System Biomarkers Market

24.1. USA Central Nervous System Biomarkers Market Overview
24.2. USA Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Central Nervous System Biomarkers Market

25.1. Canada Central Nervous System Biomarkers Market Overview
25.2. Canada Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Central Nervous System Biomarkers Market

26.1. South America Central Nervous System Biomarkers Market Overview
26.2. South America Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Central Nervous System Biomarkers Market

27.1. Brazil Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Central Nervous System Biomarkers Market

28.1. Middle East Central Nervous System Biomarkers Market Overview
28.2. Middle East Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Central Nervous System Biomarkers Market

29.1. Africa Central Nervous System Biomarkers Market Overview
29.2. Africa Central Nervous System Biomarkers Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Central Nervous System Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Central Nervous System Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Central Nervous System Biomarkers Market Competitive Landscape And Company Profiles

30.1. Central Nervous System Biomarkers Market Competitive Landscape
30.2. Central Nervous System Biomarkers Market Company Profiles
- 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Siemens Healthineers Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Thermo Fisher Scientific Inc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis

31. Central Nervous System Biomarkers Market Other Major And Innovative Companies

31.1. Merck KGaA
31.2. Eurofins Scientific
31.3. Charles River Laboratories International Inc.
31.4. PerkinElmer Inc.
31.5. Bio-Rad Laboratories Inc.
31.6. QIAGEN N.V.
31.7. Axon Neuroscience SE
31.8. Alector Inc.
31.9. Oryzon Genomics S.A.
31.10. Abastar Mdx Inc.
31.11. Banyan Biomarkers Inc.
31.12. Avacta Group PLC
31.13. Geno Technology Inc.
31.14. Anavex Life Sciences Corp.
31.15. Alseres Pharmaceuticals Inc.

32. Global Central Nervous System Biomarkers Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Central Nervous System Biomarkers Market

34. Recent Developments In The Central Nervous System Biomarkers Market

35. Central Nervous System Biomarkers Market High Potential Countries, Segments and Strategies

35.1 Central Nervous System Biomarkers Market In 2029 - Countries Offering Most New Opportunities
35.2 Central Nervous System Biomarkers Market In 2029 - Segments Offering Most New Opportunities
35.3 Central Nervous System Biomarkers Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer